2026-07-21T21:47:38Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/183212024-02-19T15:27:03Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16962
Repisalud author Ayala Gutiérrez, María Del Mar author Rubio-Rivas, Manuel author Romero Gómez, Carlos author Montero Sáez, Abelardo author Pérez de Pedro, Iván author Homs, Narcís author Ayuso García, Blanca author Cuenca Carvajal, Carmen author Arnalich Fernández, Francisco author Beato Pérez, José Luis author Vargas Núñez, Juan Antonio author Letona Giménez, Laura author Suárez Fernández, Carmen author Méndez Bailón, Manuel author Tuñón de Almeida, Carlota author González Moraleja, Julio author de Guzmán García-Monge, Mayte author Helguera Amezua, Cristina author Fidalgo Montero, María Del Pilar author Giner Galvañ, Vicente author Gil Sánchez, Ricardo author Collado Sáenz, Jorge author Boixeda, Ramon author Ramos Rincón, José Manuel author Gómez Huelgas, Ricardo author On Behalf Of The Semi-Covid-Network, 2024-02-19T15:27:03Z 2024-02-19T15:27:03Z 2021-04-23 10.3390/jcm10091844 2077-0383 Journal of clinical medicine http://hdl.handle.net/10668/17702 33922777 http://hdl.handle.net/20.500.12105/18321 Objectives: To describe the clinical characteristics and clinical course of hospitalized patients with COVID-19 and autoimmune diseases (ADs) compared to the general population. Methods: We used information available in the nationwide Spanish SEMI-COVID-19 Registry, which retrospectively compiles data from the first admission of adult patients with COVID-19. We selected all patients with ADs included in the registry and compared them to the remaining patients. The primary outcome was all-cause mortality during admission, readmission, and subsequent admissions, and secondary outcomes were a composite outcome including the need for intensive care unit (ICU) admission, invasive and non-invasive mechanical ventilation (MV), or death, as well as in-hospital complications. Results: A total of 13,940 patients diagnosed with COVID-19 were included, of which 362 (2.6%) had an AD. Patients with ADs were older, more likely to be female, and had greater comorbidity. On the multivariate logistic regression analysis, which involved the inverse propensity score weighting method, AD as a whole was not associated with an increased risk of any of the outcome variables. Habitual treatment with corticosteroids (CSs), age, Barthel Index score, and comorbidity were associated with poor outcomes. Biological disease-modifying anti-rheumatic drugs (bDMARDs) were associated with a decrease in mortality in patients with AD. Conclusions: The analysis of the SEMI-COVID-19 Registry shows that ADs do not lead to a different prognosis, measured by mortality, complications, or the composite outcome. Considered individually, it seems that some diseases entail a different prognosis than that of the general population. Immunosuppressive/immunoregulatory treatments (IST) prior to admission had variable effects. eng COVID-19 SARS-CoV-2 antirheumatic agents autoimmune diseases biological therapy glucocorticoids immune system diseases Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. research article